Multicenter Study of Risk-adapted Treatment for T-lineage ALL of Young Adults (18-59 Years Old): Evaluating the Efficacy of a Nelarabine Based Consolidation and Maintenance in High-risk Patients

Trial Profile

Multicenter Study of Risk-adapted Treatment for T-lineage ALL of Young Adults (18-59 Years Old): Evaluating the Efficacy of a Nelarabine Based Consolidation and Maintenance in High-risk Patients

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Aug 2016

At a glance

  • Drugs Nelarabine (Primary) ; Cyclophosphamide; Etoposide; Granulocyte colony-stimulating factors
  • Indications Acute lymphoblastic leukaemia
  • Focus Therapeutic Use
  • Acronyms GRAALL-2014; GRAALL-2014/T
  • Most Recent Events

    • 23 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top